OncoBindi Therapeutics

OncoBindi Therapeutics is a pre-clinical stage biotechnology company dedicated to the development of next-generation targeted cancer therapies. The company leverages its proprietary Bindi platform, which utilizes de novo computationally designed proteins that are significantly smaller and more stable than traditional antibodies. These 'Bindi' proteins are engineered into Bindi-Drug Conjugates (BDCs) to deliver toxic payloads with high precision to tumor cells while minimizing off-target toxicity. OncoBindi's lead programs focus on high-value targets such as Mesothelin for the treatment of refractory solid tumors, including ovarian and pancreatic cancers.